Genentech Eagerly Awaits FDA Word on 2nd Breast Cancer Drug

Published: Jun 11, 2012

Genentech came out with the first targeted antibody drug for breast cancer almost 15 years ago, and made headlines this week with a “supercharged” version that beats the original. What fewer people may realize is that it’s also gearing up this week to start selling a new and different targeted drug for breast cancer. The South San Francisco-based company, a unit of Roche, is eagerly awaiting word from the FDA on whether it has the green light to market pertuzumab (Perjeta) in the U.S. as a new therapy for women with breast cancer that overexpresses the HER2 protein.

Back to news